NDAINHALATIONPOWDER
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Data completeness
7/8 — Comprehensive
AIRDUO DIGIHALER (fluticasone propionate and salmeterol) by Teva is salmeterol. Approved for asthma. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AIRDUO DIGIHALER is a combination inhaled powder containing fluticasone propionate (ICS) and salmeterol (LABA) for asthma treatment. The fluticasone component exhibits high glucocorticoid receptor binding affinity to reduce inflammation across multiple cell types and mediators, while salmeterol provides long-acting beta-2 adrenergic bronchodilation and mast cell stabilization. The digitally-enabled device platform enables dose tracking and adherence monitoring.
$0.648MPart D
Peak14.7 years to LOEProduct is in peak revenue phase with modest Part D penetration (~$648K annually), indicating substantial room for market expansion and stable team investment.
Mechanism of Action
salmeterol. The mechanisms of action described below for the individual components apply to this combination product. These drugs represent 2 different classes of medications (a synthetic corticosteroid and a LABA) that have different effects on clinical, physiologic, and inflammatory indices.…
Worked on AIRDUO DIGIHALER at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.